Evaluating the Role of Chloroquine for Malaria Elimination

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

April 30, 2015

Study Completion Date

June 30, 2015

Conditions
Malaria
Interventions
DRUG

Chloroquine

Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg (expressed as mg of CQ base per kg body weight, once daily during 3 consecutive days, following the schedule 10mg/kg Day 1; 10mg/kg day 2 and 5 mg/kg day 3).

DRUG

Placebo

Placebo Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain

Trial Locations (1)

1902

Centro de Investigaçao em Saude de Manhiça, Manhiça

All Listed Sponsors
lead

Centro de Investigacao em Saude de Manhica

OTHER

NCT02698748 - Evaluating the Role of Chloroquine for Malaria Elimination | Biotech Hunter | Biotech Hunter